Form 4: Amphastar Director Michael Zasloff Receives Equity Grant

Director Michael A. Zasloff acquired 8,143 restricted stock units and 17,365 stock options in Amphastar Pharmaceuticals.

Summary

• Director Michael A. Zasloff was granted 8,143 restricted stock units (RSUs) on June 1, 2026.
• The director also received an option to purchase 17,365 shares of common stock at an exercise price of $18.42 per share.
• Both the RSUs and the stock options are scheduled to vest in full on June 1, 2027.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 37,667 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the company's operational outlook.

Positives

• Equity-based compensation aligns the interests of the director with those of long-term shareholders.
• The vesting schedule of one year encourages director retention.

Negatives

• The issuance of new equity awards results in minor dilution to existing shareholders.

Risks

• Market volatility could impact the future value of the granted equity awards.
• The exercise price of $18.42 is subject to market fluctuations relative to the company's future stock performance.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the pharmaceutical industry to ensure governance alignment and incentivize long-term strategic oversight.

Comparison to Industry Standards

• The use of RSUs and stock options as part of director compensation is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• A one-year cliff vesting period is a common retention mechanism for board members in the life sciences sector.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on June 1, 2027.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Equity Compensation, Director Compensation